BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cacabelos R, Carril JC, Corzo L, Fernández-Novoa L, Pego R, Cacabelos N, Cacabelos P, Alcaraz M, Tellado I, Naidoo V. Influence of Pathogenic and Metabolic Genes on the Pharmacogenetics of Mood Disorders in Alzheimer's Disease. Pharmaceuticals (Basel) 2021;14:366. [PMID: 33920985 DOI: 10.3390/ph14040366] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Cacabelos R, Carril JC, Corzo L, Pego R, Cacabelos N, Alcaraz M, Muñiz A, Martínez-Iglesias O, Naidoo V. Pharmacogenetics of anxiety and depression in Alzheimer's disease. Pharmacogenomics 2023;24:27-57. [PMID: 36628952 DOI: 10.2217/pgs-2022-0137] [Reference Citation Analysis]
2 Nagata T, Shinagawa S, Inamura K, Shigeta M. Pathogenesis and Personalized Interventions for Pharmacological Treatment-Resistant Neuropsychiatric Symptoms in Alzheimer’s Disease. JPM 2022;12:1365. [DOI: 10.3390/jpm12091365] [Reference Citation Analysis]
3 Cacabelos R, Naidoo V, Martínez-iglesias O, Corzo L, Cacabelos N, Pego R, Carril JC. Personalized Management and Treatment of Alzheimer’s Disease. Life 2022;12:460. [DOI: 10.3390/life12030460] [Reference Citation Analysis]
4 Cacabelos R. What have we learnt from past failures in Alzheimer's disease drug discovery? Expert Opin Drug Discov 2022;:1-15. [PMID: 35129021 DOI: 10.1080/17460441.2022.2033724] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Cacabelos R, Naidoo V, Martínez-iglesias O, Corzo L, Cacabelos N, Pego R, Carril JC. Pharmacogenomics of Alzheimer’s Disease: Novel Strategies for Drug Utilization and Development. Methods in Molecular Biology 2022. [DOI: 10.1007/978-1-0716-2573-6_13] [Reference Citation Analysis]